Korea's Celltrion Signs Deal with Hungary's Egis Pharmaceuticals to Sell Biosimilars In Former Soviet Republic Countries, Eastern Europe
This article was originally published in PharmAsia News
SEOUL - South Korea's Celltrion has signed a deal with Hungary's Egis Pharmaceuticals to sell Celltrion's future biosimilar products in the former Soviet Republic countries and Eastern Union
You may also be interested in...
The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.
After holding a 51% stake in Egis for 18 years, France's mid-sized pharma company Servier is now offering nearly $483 million to buy the rest of the Hungarian generics company.
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma